My group works on developing single-cell microtechnologies to interrogate functional cellular heterogeneity and inter-cellular signaling network in human health and disease. We developed a microchip technology that permits co-detection of 42 immune effector proteins from single cells, representing the highest multiplexing to date for a single-cell protein secretion assay. This microchip called IsoCode has been integrated with a single-cell automation system called IsoLight to truly enable robust and reproducible functional proteomics analysis at the single-cell level. It has been commercialized at IsoPlexis and used by 10+ pharmaceutical companies including Novartis and Kite Pharma (a Gilead Company) to evaluate cell-based immunotherapy products. We are also working to develop high-throughput microtechnologies for co-analysis of single-cell epigenomic, transcriptomic, and proteomic profiles. Applying these technologies to human hematopoietic malignancies, systemic autoimmune diseases, and engineered T cell therapies has revealed new biological insights and new targets potentially for early diagnosis or therapeutic intervention

Awards and Achievements

  • NSF CAREER Award